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Introduction: Osteonecrosis of the femoral head (ONFH) is a degenerative disease progressing to a femoral head
(FH) collapse. Injection of osteoprogenitor cells like bone marrow mesenchymal stromal cells (BMSCs) into the FH
appears to be a good therapeutic treatment. However, safety and efficacy of BMSCs to treat bone defect are the
main preclinical data required for clinical application. Efficacy and the lack of risk of cell transformation after
amplification of BMSCs have been extensively described. The main objectives of this study were to develop a
simple and usable procedure for clinicians and control its feasibility by evaluating the biodistribution of BMSCs after
injection into the FH in a large animal model. The impact of this approach was evaluated on one natural pig ONFH.
Methods: BMSCs were directly injected in the pig FH, and then the biodistribution of grafted cells was detected by
quantitative real-time polymerase chain reaction, cytometry, or a combination of classic histology analysis and in situ
hybridization (ISH). BMSC efficacy on bone regeneration was evaluated by magnetic resonance imaging (MRI) and histology.
Results: After 30-minute and 24-hour follow-up, grafted cells were detected at the injection site and no BMSCs were de-
tected in filter organs or body fluids. The combination of classic histology analysis and ISH showed a good homogeneity of
cell distribution in FH. Local delivery of BMSCs onto a bone scaffold associated with bone formation in vivo confirmed
the preferential tropism of BMSCs to the bone tissue as well as their efficacy to form bone. Treatment of a natural pig
ONFH by autologous BMSCs indicated a beginning of bone healing as early as 2 weeks with a complete healing after
9 weeks. At this stage, MRI and histological analysis were similar to those of a normal FH.
Conclusions: Intra-osseous injection of BMSCs in FH seems to be a good strategy for ONFH treatment as the safety
concerning the biodistribution of BMSCs is ensured. Moreover, the efficacy of BMSCs in natural ONFH seems to indicate
that this is a promising approach. Altogether, these results constitute the preclinical data necessary for the setup of a
clinical application with expanded BMSCs in the context of advanced therapy medicinal products.* Correspondence: nathalie.chevallier@efs.sante.fr
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Osteonecrosis of femoral head (ONFH) is a progressive
degenerative disease due mainly to the loss or comprom-
ise of blood flow to the femoral head (FH) and bone
progenitor deficiency. If the necrotic bone lesion is not
treated early, it may progress to a collapse of FH and re-
quire a total hip replacement [1]. This painful disorder
commonly occurs in a young population (mean age of
36 years) [2]. To avoid arthroplasty, many conservative
procedures are used in the early pre-collapse stage of
ONFH, including core decompression associated (or
not) with autologous bone marrow (BM) grafting [3,4].
However, even if positive results are obtained, the treat-
ment of the ONFH continues to be a challenging prob-
lem for orthopedic surgeons. Bone tissue engineering,
using mesenchymal stromal cells (MSCs), provides a
promising approach [5]. Indeed, MSCs used in various
animal models of bone repair were described to have
significant osteogenic potential [6-8], and promising case
reports have been published [9,10].
MSCs have the potential to migrate and the capacity
to be mobilized to sites of injury. However, it has been
shown that injected MSCs via intra-artery and intraven-
ous (IV) portals lead to their detection in the lungs
within 15 minutes and then in the liver, kidneys, and
spleen, indicating a large spectre of cell dissemination
[11-14]. Several articles seem to indicate that if the cells
are injected in the site of injury, they stay preferentially
and with a better viability to this site compared with an
IV injection [13-15]. As bone is the physiological envir-
onment of BM-MSCs (BMSCs), we hypothesized that a
local delivery of BMSCs into the FH during surgery
would facilitate their location and participation in tissue
regeneration.
For clinical applications of this advanced therapy me-
dicinal product (ATMP), preclinical data on BMSC
safety concerning their innocuity and their biodistribu-
tion after their injection are required [16,17]. It has been
previously shown that there is no risk of BMSC trans-
formation after their amplification and graft in vivo
[18]. Currently, it is necessary to demonstrate the hom-
ing pattern of the injected cells to avoid inappropriate
differentiation in other organs or the development of
cancer cells [18-21]. Cells spreading can be impacted
by the route of administration [14]. Therefore, to assess
the biodistribution, it is essential to administer the cells
by the exact portal that will be used in the clinic. Pre-
clinical recommendations require to perform the test
with human BMSCs (hBMSCs) on a large animal
model of the disease [17]. The pig is considered a
translational model in biomedical research because of
anatomical, physiological, and biochemical similarities
to humans and has been commonly used to obtain pre-
clinical data [22,23].The goals of our work were to develop a new thera-
peutic treatment of ONFH by injecting BMSCs directly
into the FH without using any BMSC carrier and to
make the orthopedic surgery procedure easy and suitable
for clinicians. One essential piece of preclinical data re-
quired for this procedure is the analysis of their biodis-
tribution in a large animal model. To this end, human or
pig BMSCs were directly injected in the pig FH as is
done in the clinic for the injection of the concentrated
BM with a trocar of 4 mm in diameter. To check
whether grafted BMSCs are confined to the target site
and not found in proximal tissues or filter organs such
as lungs and kidneys or body fluids (blood and BM), we
used different highly sensitive techniques like cell cy-
tometry analysis and an innovative approach using
species-specific human primers for quantitative real-
time polymerase chain reaction (qPCR). In parallel, to
localize the human cells, we conducted classic histology
analysis associated with in situ hybridization (ISH) of
the human Alu sequence. To confirm the preferential
tropism of BMSCs to bone, a local delivery of BMSCs
onto a bone scaffold in a mouse model was performed




Ethical approval for all animal experimentation was ob-
tained from the local ethics committee (ComEth Afssa/
ENVA/UPEC, Maisons-Alfort, France) (#12-036) in ac-
cordance with the European Guidelines for Animal Care
(Directive 2010/63/EU).
Pigs
Five female pigs (hybrid of Landrace and large white
pigs) with a weight of 35 to 50 kg and age of 3 to
6 months were used (Lebeau Christian, Gambais,
France). Pigs were managed in accordance with the in-
structions of the ethics committee.
Mice
Two severe combined immunodeficiency (SCID) mice
(males, 7 weeks old) purchased from Charles River
Laboratories (Chatillon, France) were used for the ectopic
implantation procedure. The mice were anesthetized with
isoflurane (Abbott, Rungis, France) and were eutha-
nized with an overdose of pentobarbital (Centravet,
Maisons-Alfort, France).
Biomaterials
Scaffolds of Tutoplast Process Bone (Tutogen Medical,
Metz, France) were derived from human cancellous
bone. The Tutoplast process consisted of a delipidiza-
tion, an osmotic cell destruction treatment, hydrogene
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the non-collagen proteins followed by a solvant dehy-
drated step and finally a γ-irradiation procedure. Frag-
ments of 2 to 4 mm were cut manually and were stored
at room temperature (RT) under sterile condition. Bone
scaffolds of equivalent size, volume, and weight (8.0 ±
1.0 mg) were used in this study to ensure a comparable
surface area for in vivo analyses.
Bone marrow mesenchymal stromal cell cultures
Pig BMSCs were isolated from BM (5 to 10 mL) of pig
humerus (pBMSCs). Human MSCs were isolated from
BM (3 to 5 mL) collected from the iliac crest (hBMSCs)
of patients undergoing standard BM transplantation pro-
cedures (AP-HP Hôpital Henri Mondor, Créteil, France),
after having received their informed consent in accord-
ance with the Declaration of Helsinki. The project was
approved by the Ethical Committee of Ile de France
(section 4 #DC-2009-1049). pBMSCs and hBMSCs were
cultured in alpha-modified Eagle’s medium (αMEM)
(PAA, Les Mureaux, France) supplemented with 10% of
foetal calf serum (FCS) (Stem Cell Technologies, Grenoble,
France) and 0.5% ciprofloxacine (Bayer Pharma, Puteaux,
France). The hBMSCs used in this study were positive for
CD90, CD105, and CD73 and negative for CD34 and
CD45 and were able to differentiate into osteogenic, adi-
pogenic, and chondrogenic lineages (data not shown) as
previously described [7,24,25].
Functional characterization
To characterize pBMSCs, their capacity to differentiate
into mesenchymal lineages was assessed. For osteogenic
differentiation, at 50% confluence the growth medium
was replaced by αMEM-10% FCS supplemented with
50 μM L-ascorbic acid-2-phosphate (AA), 10 mM βGly-
cerophosphate (βGly), 0.1 μM dexamethasone (Dex)
(Sigma, Saint Quentin Fallavier, France), and 100 ng/mL
rhBMP2 (recombinant human bone morphogenetic pro-
tein 2, Inductos; Laboratoire Wyeth Pharmaceuticals,
Philadelphia, PA, USA). On day 10, the monolayers were
fixed in 70% ethanol (Cooper, Melun, France) for 1 hour
at 4°C and stained for 15 minutes with Alizarin Red S
(Sigma) at RT.
For adipogenic differentiation, at 80% confluence the
medium was replaced by a high-glucose medium (Invi-
trogen, which is part of Life Technologies, Villebon sur
Yvette, France) supplemented with 10% FCS, 0.1 mM
Dex, 0.2 mM indomethacin, 0.01 mg/mL insulin, and
0.5 mM IBMX (Sigma). On day 10, the monolayers were
fixed by using 4% paraformaldehyde (VWR, Fontenay
Sous Bois, France) for 5 minutes at RT and stained for
15 minutes with 0.3% Oil Red O (Sigma)/60% isopropa-
nol (VWR). Chondrogenic differentiation was performed
in pellet culture by using Stempro, a ChondrogenesisDifferentiation Kit (Life Technologies), as described by
the manufacturer. On day 21, pellets were fixed in 4%
formaldehyde (Sigma) and embedded in paraffin. Sec-
tions (3 μm) were stained with Alcian Blue 8GX (Sigma)
as described by the manufacturer and counterstained
with hematoxylin (Sigma).
Surgical procedure in pigs
Pigs were managed in accordance with the instructions
of the ethics committee. Access to FH was done in ac-
cordance with the previously described protocol by a per-
cutaneous approach of the hip [26]. Pigs received an
injection of 140 × 106 autologous pBMSCs (n = 1) or
hBMSCs (n = 2) in 7 mL of 5% human serum albumin
(Albunorm; Octapharma, Boulogne-Billancourt, France),
and one pig served as a negative control. To push all the
cells inside the FH and to allow the cells to migrate cor-
rectly to the necrotic site, a volume of air (2 to 5 mL)
was injected and then the trocar was let 5 minutes be-
fore being removed.
Blood was collected before (T0) and after injection
with a kinetic from 1 minute to 24 hours. Liver, kidneys,
spleen, and lungs were collected at either 30 minutes or
24 hours after injection. BM was collected before (T0)
and 24 hours after injection. Injected FH and adjacent
tissues (that is, capsule, periarticular muscles, gluteus
maximus muscle, and round ligament) were analysed
30 minutes after injection. Non-injected pig served as a
negative control. Organs were dissected into several
pieces and ground on a cell strainer with a suitable pis-
ton and used for cytometry and molecular biology.
Cell labeling with DiOC18
Before injection, pBMSCs (20 × 106 cells/mL) were incu-
bated in 10 μg/mL of DiOC18 (3, 3′-dioctadecyloxacarbo-
cyanine perchlorate) solution (Molecular Probes, part of
Life Technologies) containing 3% FCS for 20 minutes at
37°C [27]. Finally, pBMSCs were washed with 1X Hanks’
balanced salt solution (PAA) three times to get rid of dye
remnant and re-suspended in 5% human serum albumin
(Albunorm; Octapharma).
Flow cytometry
Ground organs and body fluids of pigs that received an
hBMSC injection were stained for BMSC marker CD73-
APC (Becton, Dickinson and Company, Franklin Lakes,
NJ, USA) for 15 minutes. Then the different samples of
pigs that received an injection of DiOC18
+ pBMSCs (n = 1)
or hBMSCs (n = 2) were examined by using FACSCanto™
II (Becton, Dickinson and Company). The data were
analysed by using BD FACS DIVA™ software (Becton,
Dickinson and Company). The efficacy of labeling was
checked before injection with positive expression of
stained cells defined as fluorescence greater than 95% of
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DiOC18 or hBMSCs not labeled CD73.
DNA purification and quantitative real-time polymerase
chain reaction
Two specimens were sacrificed 30 minutes and 24 hours
after hBMSC injection. Samples were immediately placed
in DNA lysis buffer (Qiagen, Courtaboeuf, France) after
collection. Total DNA was isolated by using a QIAmp
DNA Mini Kit for blood, BM, organs, and tissue samples
and using a QIAmp DNA Investigator Kit for FH samples
as described by the manufacturer (Qiagen). FH samples
were previously pulverized to a fine powder by using a
ceramic ball of 6.35 mm and a Fast Prep System (MP
Biomedical, Santa Ana, CA, USA). The human genomic
DNA (gDNA) obtained was quantified by using human
TaqMan Copy Number Reference Assay, RNase P (Ap-
plied Biosystems, part of Life Technologies, Courta-
boeuf, France) with a 7500HT Fast Real-Time PCR
System (Applied Biosystems). hBMSC standard range
was realized with decreasing concentrations of hBMSC
gDNA diluted in pig gDNA (5 ng/μL). The straight
equation (y = −3.526 × 38.163; R2 = 0.9983) of standard
curve had permitted us to obtain the number of cells
corresponding to detected cycle threshold (Ct).
In situ hybridization of human Alu sequences
After euthanasia, half of FH was removed 30 minutes
after hBMSC injection, fixed for 48 hours, and decalci-
fied in 4.13% EDTA solution (pH 7.4) (Sigma). After de-
hydration, clearing, paraffin-embedding, and cutting
steps, ISH was performed on the FH sections as previ-
ously described by Redwine and Armstrong [28]. Locked
nucleic acid-based probes were ordered from Exiqon,
Inc. (Woburn, MA, USA), and the sequence used was
/5DigN/TCTCGATCTTCCTGACCTCATGA/3Dig_N/.
Sections were deparaffinized, rehydrated, washed, and
treated with 3% hydrogen peroxide for 15 minutes.
After washing, sections were treated in 0.1 M triethanola-
mine pH 8.0 and 0.25% acetic acid for 20 minutes at RT
and pre-hybridized for 1 hour at 56°C in buffer containing
4X SSC (sodium saline citrate) (VWR), 50% deionized
formamide, 1X Denhardt’s solution, 5% Dextrane Sulfate,
and 100 μg/mL Salmon Sperm DNA. Hybridization buffer
was replaced by fresh buffer containing 70 nM of Alu
probe and was denatured for 5 minutes at 95°C.
Hybridization was carried out for 2 hours at 56°C in a
wet chamber. Slides were washed twice for 5 minutes in
2X SSC and twice for 5 minutes in 0.5X SSC at 56°C
each. Signals were detected by using anti-DIG horseradish
peroxidase-conjugated Fab fragments (Roche, Boulogne
Billancourt, France) and diaminobenzidine (Dako,
Carpinteria, CA, USA) as substrate. Sections were
counterstained with Gill-2 hematoxylin (Thermo ShandonLtd., Runcorn, UK). Two negative controls were produced
to compare and ensure consistent interpretation: negative
controls of pig FH injected with human cells in omitting
Alu probe and sections of FH injected with physiological
saline only exposed to Alu probe. Slides were observed by
using a DMRXA microscope (Leica, Nussloch, Germany).
Magnetic resonance imaging
Magnetic resonance imaging (MRI) was performed on a
1.5-T MRI device (Siemens Avanto, Erangen, Germany).
Pigs were in the supine position, and their hind legs
were tied in extension. T1-weighted and T2 with fat sat-
uration (T2 FS)-weighted sequences were obtained in
the coronal planes.
Ectopic implantation procedure in immunodeficient mice
Six subcutaneous dorsal pockets (0.5-cm incisions) were
prepared in each of the SCID mice. In each pocket, one
scaffold was implanted and 300,000 pBMSCs (P2) were
injected onto the scaffold in the pocket. The skin was
closed with 5-0 sutures (Ethicon, San Lorenzo, Puerto
Rico, USA). Cell-free scaffolds were implanted under
similar conditions and served as controls. pBMSCs from
porcine BM of three independent pigs were tested in du-
plicate (n = 6 scaffolds).
Histology
Pig femoral head
Pig FHs were fixed with 4% formaldehyde solution
(VWR), decalcified in 6.8% nitric acid (VWR) for
2 weeks, and rinsed abundantly in tap water before em-
bedding in paraffin. Sections (3 μm) were stained with
Masson’s Tri-chrome (hematoxylin: nuclear staining;
acid fuchsin/xylidine ponceau: cytoplasmic staining; light
green SF yellowish: collagen staining; all from VWR).
Images were visualized by standard light microscopy and
captured by using a UC30 Digital Color Camera and
CellSens Entry software (Olympus, Rungis, France).
Mice scaffolds
After 7 weeks, scaffolds were excised from mice and im-
mediately fixed in 70% ethanol, decalcified for 3 hours in
6.8% nitric acid (VWR), and rinsed in tap water before
embedding in paraffin. Sections (3 to 5 μm) were stained
with Masson’s Tri-chrome. Fifteen sections of each sam-
ple were analyzed (five at the beginning, five in the mid-
dle, and five at the end).
Results
Having previously described that only 7 mL can be
injected in the FH (data not shown) [29] and published
that a concentration of 20 × 106 BMSCs/mL is efficient
to induce bone formation [7,8,24], we decided for the fu-
ture clinical protocol to inject 140 × 106 BMSCs in the
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three different protocols were performed: two with hu-
man cell origins (hBMSCs) with a 30-minute or 24-hour
follow-up and one with autologous pig cells (pBMSCs)
with a 24-hour follow-up. After injection, the cells were
monitored by flow cytometry, molecular biology, or hist-
ology, at different times and in various organs.
Biodistribution of human bone marrow mesenchymal
stromal cells after intra-osseous injection in pig femoral
head
Preclinical recommendation required us to assess the
biodistribution with human cells [17], and hBMSCs were
injected in the pig FH. Compared with unlabeled hBMSCs






























Figure 1 Biodistribution analysis of injected human bone marrow mesenc
hBMSCs were injected in the subchondral area of pig femoral head and an
after injection with a kinetic of 1 minute to 24 hours. (b) Liver, lungs, splee
injection. Periarticular muscles and round ligament were collected 30 minu
24 hours after injection. Dark histogram: unstained hBMSCs; grey histogram
cells of a non-injected pig.all positive for this marker (grey histogram) (Figure 1). Col-
lected blood at 0 (before injection), 1, 5, 15, and 30 minutes
and 1 hour and 24 hours post-injection and collected BM
at 0 minutes and 24 hours post-injection were analysed by
flow cytometry (Figure 1A, C). Compared with the control
blood and control BM (white histogram), no positive cells
for hCD73 (grey histogram) were found. Twenty-four
hours after injection, no hCD73-positive cells were de-
tected in the liver, lungs, spleen, and kidneys or in adja-
cent tissues such as periarticular muscles and round
ligament (Figure 1B). Only normal tissue-specific cells
were found (white histogram).
To confirm the cytometry study, an approach by
species-specific qPCR was developed. To quantify the
presence of human cells injected in the porcine FH, aBlood T1 min Blood T5 min
Blood T1 h Blood T24 h
Spleen Kidneys
Bone Marrow T0 Bone Marrow T24 h
-APC
c
hymal stromal cells (hBMSCs) in pig femoral head by flow cytometry.
alysed at different time point. (a) Blood was collected before (T0) and
n, and kidneys were analysed either at 30 minutes or 24 hours after
tes after injection. (c) Bone marrow was collected before (T0) and
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Figure 2 Tracking of injected human cells in pig femoral head by molecular biology. (a) Standard curve of human cells quantified by using
human TaqMan Copy Number Reference Assay, RNase P. (b) Conversion of average cycle threshold (Ct) to corresponding number of cells from
the straight equation of the standard curve (y = −3.526 × 38.163). (c) Detection (Ct) of injected cells in pig femoral head samples (n = 24) by
reverse transcription-quantitative real-time polymerase chain reaction with human RNase P.
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gDNA was serially diluted in pig DNA. The linear curve
obtained indicated that our qPCR primer (RNase P) was
100% efficient (R2 = 0.99) (Figure 2a). This curve allowed
us to quantify the exact number of cells up to 13 human
cells when mixed in 3,200 pig cells. With this standard
curve, we determined our sensitivity threshold at 0.41%
(Figure 2B). Below 34 cycles, the standard curve was not
linear; human cells were detected but were not quantifi-
able. Two independent assays were performed: one with
a 30-minute follow-up and the other with a 24-hour
follow-up. In both cases, no human cells were found in
adjacent tissues of FH (n = 6 samples per tissue) or in
blood, lungs, liver, spleen, and kidneys (n = 4 samples for
blood and n = 6 samples per organ). BM of the non-
injected pig humerus was also tested, and as in the other
organs, no human cells were found (n = 4) (Table 1).
As expected, 30 minutes after human cell injection,
the injected hBMSCs were found in the FH. All FH
samples tested by RNase P qPCR were positive, with acycle threshold (Ct) average of 30.8 ± 0.9, which indicated
an average of 147 ± 21 cells per 10 mg of FH samples (n =
24) (Figure 2c).
Histological analysis was performed to localize the
injected cells in the FH. Normal FH showed trabecular
bones surrounded by BM endowed with hematopoietic
cells and adipocytes (Figure 3a, b). After hBMSCs injec-
tion, part of the BM was replaced by large non-
hematopoietic cells (arrows). These cells were localized
close to trabeculae and seemed to be attached to the
bone surface (Figure 3c, d). To confirm histologic find-
ings, a human-specific Alu probe was used for Alu-ISH
(Figure 3e-i). Positive brown nuclei staining was consid-
ered positive for Alu-ISH. Negative controls did not show
any brown cytoplasmic or nuclear staining (Figure 3f, g).
The sections of FH with injected human cells showed
positive dark brown nucleus staining, whereas other cells
were stained only with hematoxylin (Figure 3h, i). Human
cells were well distributed inside the pig FH but were lo-
calized in the FH subchondral area on either side of the
Table 1 Tracking of injected human bone marrow mesenchymal stromal cells in vivo by molecular biology: detection
by quantitative real-time polymerase chain reaction of the human RNase P gene
Samples Delay after injection RNase detection






Pig sample after hBMSCs injection Adjacent tissues of FH n = 6
samples per tissue















Bone marrow n = 4 samples per condition 0 No detection
24 hours
FH, femoral head; hBMSCs, human bone marrow mesenchymal stromal cells.
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attached on the bone trabeculae (Figure 3i).
Biodistribution of autologous pig bone marrow
mesenchymal stromal cells after intra-osseous injection in
pig femoral head
To confirm our previous results, we wanted to use au-
tologous pig cell grafting. BM from pig humerus was
used to isolate pBMSCs and then these cells were char-
acterized by their differentiation properties (Figure 4a-c).
Porcine cells deposited an extensive mineralized
matrix when cultured for 10 days in the osteogenic
medium as demonstrated by strong Alizarin Red stain-
ing (Figure 4a). These porcine cells also efficiently
differentiated into the adipogenic lineage, as indi-
cated by Oil Red O staining of lipid droplets in the
cytoplasm after 10 days of culture in an adipogenic
medium (Figure 4b). The chondrogenic potential of
pBMSCs was also highlighted by Alcian Blue staining
after 3 weeks in a chondrogenic medium. This blue
staining revealed a homogenous deposition of proteo-
glycan within the whole section of the pellet culture,and the counterstaining with hematoxylin showed the
presence of chondrocyte-like cells in purple inside the
lacunae (Figure 4c).
To be able to follow the autologous injected cells in
the pig FH, pBMSCs were stained with DiOC18 before
injection. Compared with the unstained pBMSCs (con-
trol), indicated by dark histogram, the pBMSCs stained by
DiOC18 (grey histogram) showed a 2 log switch of fluores-
cence, indicating that 100% of pBMSCs were positive for
DiOC18 (Figure 4d). No positive cells were found in the
different tissues and fluid tested in different times (blood
and organs). Only normal tissue-specific cells were found
(white histogram).
Bone tropism of bone marrow mesenchymal stromal cells
To confirm that BMSCs have a preferential tropism for
the bone surface, we assessed the capacity of the cells to
locate and induce bone formation after a local delivery
of the cells on a bone scaffold. For this purpose, an im-
munodeficient mouse model of ectopic implantation was
performed. In the unseeded controls, no new bone for-

















Figure 3 Detection of injected cells in pig femoral head (FH) 30 minutes after human bone marrow mesenchymal stromal cell (hBMSCs)
injection. (a-e) Masson’s Tri-chrome staining. (a, b) Normal pig FH sections. (c-e) Injected pig FH sections. Arrows indicate the hBMSC area. (e)
Localization of sections (c), (d), (h), and (i). (f-i) In situ hybridization of human Alu sequences (Alu-ISH). (f) Negative control tissue of pig FH injected
with human cells in omitting Alu probe stained with the hematoxylin only. (g) Negative control tissue of pig FH injected with physiological saline
without human cells, with Alu probe and hematoxylin counterstaining. (h, i) Injected pig FH with human cells detected by Alu-probe
staining and counterstained with the hematoxylin. The positive nuclei for Alu-probe staining appear in dark brown (arrows). Magnifications:
10× (a, c, f-h), 20× (b, d), 1× (e), and 40× (i).
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(Figure 5a, b). In contrast, when pBMSCs were added
onto the scaffold during the surgery, histological analysisrevealed new bone formation with bone tissue contain-
ing osteocyte-like cells and osteoblast-like cell lining
at the surface (Figure 5c, d). Altogether, this result
40 µm40 µm40 µm ba c
Blood T0 Blood T1 min Blood T5 minPig-BMSCs























Figure 4 Biodistribution analysis of injected autologous pig bone marrow mesenchymal stromal cells (BMSCs) in pig femoral head by flow
cytometry. Characterization of pig BMSCs in vitro with (a) osteoblastic differentiation with an extensive mineralized matrix of calcium
hydroxyapatite crystals stained in red by Alizarin Red S, (b) adipocyte differentiation with adipocytes containing lipid droplets in the cytoplasm
stained in red by Oil Red O, and (c) chondrogenic differentiation with chondrocyte-like cells stained by hematoxylin in purple and surrounded by
glycosaminoglycan-rich extracellular matrix stained in blue by Alcian Blue. (d) Biodistribution analysis by flow cytometry follow-up during 24 hours
(n = 1) of autologous labeled DiOC18-FITC BMSCs injected in subchondral area of pig femoral head. Dark histogram: unstained pig BMSCs; grey
histogram: stained DiOC18-FITC pig BMSCs; and white histogram: negative control cells of a non-injected pig. DiOC18, 3, 3′-dioctadecyloxacarbocyanine
perchlorate; FITC, fluorescein isothiocyanate.
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surface and had the capacity to induce bone formation
in vivo.
Cell therapy of natural osteonecrosis of femoral head
nONFH was diagnosed in pig. Compared with coronal
MRI images of control pig FH (Figure 6a, f ), nONFH
was observed by a classic MRI appearance of osteo-
necrosis with a front regeneration: a geographical region
of decreased marrow signal within the normally bright
fat of the FH on T1-weighted images and mixed low/
high signal on T2 FS-weighted images (Figure 6b, g).The front of regeneration delimitated a fatty necrotic
area in the epiphysis of high T1 signal and a neutral sig-
nal on T2 FS-weighted images. One month after the first
MRI, a new MRI analysis was conducted before a pos-
sible cell therapy. The diagnosis of osteonecrosis and the
absence of spontaneous bone regeneration were con-
firmed by the observation of results similar to the previ-
ous analysis (Figure 6c, h).
After pBMSC injection in the center of nONFH, the
pig was able to bear its full weight on the day of surgery.
After 2 weeks, the front of regeneration had partially
disappeared (Figure 6d, i). Nine weeks after pBMSC
dc 400 µm 50 µm














Figure 5 Histological analysis of in vivo bone formation after 7 weeks of ectopic implantation into immunodeficient mice. Scaffolds (a, b) without pig bone
marrow mesenchymal stromal cells (pBMSCs) (a) Magnifications: 4×, (b) Magnifications: 20×. (c, d) with 300,000 pBMSCs directly loaded onto the bone
scaffold during the surgery. Cells from three different pigs were tested. (c) Magnifications: 4×, (d) Magnifications: 20×. Decalcified implants (n = 6 per
condition) were embedded in paraffin and stained with Masson’s Tri-chrome (blue/green = collagen and non-mineralized bone; red = mineralized bone
scaffold; purple = nuclei; and pink = cytoplasm). Dotted lines correspond to the areas of new bone formation. NB, new bone; Sc, scaffold ; FT, fibrous tissue.
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collapse and the front of regeneration was almost invis-
ible. MRI FH images presented almost normal fatty bone
medullary signal (Figure 6e, j). Then histological analysis
was performed. Bone tissue showed a regular trabecular
bone network with a normal growth plate in the middle
of the FH (Figure 6k). The trabecular bones contained
osteocytes and were surrounded by a normal BM consti-
tuted with hematopoietic cells and adipocytes (Figure 6l).
No features of osteonecrosis such as osteocyte or adipocyte
necrosis were visible. Only normal bone was observed.
Discussion
For ATMPs like hBMSCs, regulatory authorities require
safety data concerning their innocuity and their biodis-
tribution after their injection on a large animal model
[16,17]. It has been previously shown that there is no
risk of hBMSC transformation after their amplification
and graft in vivo [18]. Although the safety and efficacy of
BMSC injection have been tested mainly by using immu-
nodeficient mice, we used the pig as a preclinical model,
and for the first time we showed the biodistribution of
cell injection by using either autologous pBMSCs or
hBMSCs. Our results indicate that BMSCs remained
confined at the site of injection and have the potential to
repair the osteonecrosis in vivo. Currently, there is nosingle satisfactory method for assessing biodistribution.
Several non-invasive, imaging-based monitoring methods
have been used to track cell transplants via radiolabels,
ferromagnetic particles (that is, iron oxide nanoparticles),
and genetically modified cells engineered to express re-
porter transgenes but these approaches can functionally
alter the cells [30-34]. To avoid alteration of BMSC func-
tionality, hBMSCs were directly injected in the FH. There-
fore, we used several highly sensitive techniques for cell
detection, like flow cytometry, real-time qPCR, histology,
and Alu-ISH analysis, in order to validate our results.
qPCR is a quantitative and highly sensitive technique
which allows the presence of a few human cells to be de-
tected even when they are mixed with pig DNA. Our
standard curve indicated that we were able to determine
the exact number of human cells up to 13 human cells
mixed in 3,200 pig cells. Below, human cells were detected
but their number was not quantifiable. In the present
study, our data demonstrated that after direct loading,
grafted hBMSCs did not have unwanted homing. Indeed,
no human cells were detected throughout the kinetic,
from 30 minutes to 24 hours after implantation in tissues
such as blood, BM, lungs, liver, spleen, and kidneys.
Similarly, in tissues located near the drilling injection,
such as capsule, round ligament, periarticular muscles,












Figure 6 Cell therapy of natural femoral head osteonecrosis (nONFH) in the pig with injection of 140 × 106 autologous pig bone marrow
mesenchymal stromal cells (pBMSCs) (n = 1) in femoral head (FH). (a) to (j) Coronal magnetic resonance imaging (MRI) analysis: red arrows
indicate necrotic area, green dashed lines indicate drilling rearrangement, and blue arrows indicate repair area. (a) to (e) T1-weighted image. (f)
to (j) T2-FS (fat saturation)-weighted image. (a) and (f) Normal pig FH (negative control). (b) and (g) Diagnosis of nONFH in pig FH. (c) and (h)
Confirmation of nONFH in pig FH 1 month after MRI diagnosis. (d) and (i) Pig FH with nONFH 2 weeks after injection of autologous pBMSCs. (e)
and (j) Pig FH with nONFH 9 weeks after injection of autologous pBMSCs. (k) and (l) Histological analysis of pig FH with nONFH 9 weeks after
injection of autologous pBMSCs stained with Masson’s Tri-chrome (blue/green = collagen and non-mineralized bone; red = mineralized bone;
purple = nuclei). Magnifications: 1× (k) and 20× (l). BM, bone marrow; Oc, osteocytes; TB, trabecular bone.
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the implantation site, in the FH, 30 minutes after cell
graft with an average of 147 ± 21 human cells per 10 mg
of FH.
The drawback of this technique is the difficulty to
clearly discriminate between viable BMSCs or macro-
phages which contain phagocytized human cell frag-
ments [35]. To this end, qualitative analyses were
performed. Because of their high repetition and species
specificity, Alu sequences are a marker of choice to use
ISH to detect few human cells in pig tissue [16]. Thissensitive qualitative technique precisely localizes the
cells in FH and indicates a good homogeneity of human
cell distribution with the histological analysis. These re-
sults confirmed that grafted hBMSCs remained on tra-
beculae and provided evidence of the absence of
spreading of these cells to the other tissues. Even if cells
are described as immune-privileged with immunomodu-
latory, anti-inflammatory, immunosuppression potential
and are used for xenogenic transplantation [36,37], we
wanted to confirm our results by using autologous cell
grafting. For this purpose, pig cells were stained with
Lebouvier et al. Stem Cell Research & Therapy  (2015) 6:68 Page 12 of 14DiOC18, a green fluorescent membrane dye which does
not induce adverse cellular effects [38]. The only draw-
back is that the cells can lose half of their fluorescence
after doubling. However, human and pig BMSC doubling
time is between 50 and 55 hours [7,39], and our follow-
up does not exceed 24 hours. One day after pBMSC in-
jection in the FH, the flow cytometry analysis indicated
that the injected cells were detected neither in blood nor
in filter organs.
In contrast to studies in which cells are injected intra-
venously, our results confirm that injected cells prefer-
entially stay in the injected tissue [13,14,40,41]. In our
case, this can be explained by the fact that bone is the
physiological niche of BMSCs. We confirmed their trop-
ism for the bone surface with the ectopic bone implant-
ation model in immunodeficient mice as only bone
scaffold receiving pBMSCs during surgery gives bone
formation. Moreover, our results with pBMSCs are in
accordance with recent data we published showing that
hBMSCs stay on the scaffold and do not migrate to
other organs and this was the case throughout the
6 weeks of the study [42]. On the other hand, our data
of grafted autologous pBMSCs in nONFH in the pig
support that a local delivery of BMSCs into the FH dur-
ing surgery facilitates their attachment and their partici-
pation in tissue regeneration. Altogether, these results
indicate that a direct injection of BMSCs on the bone
site is a safe procedure, even if a 4-mm diameter trocar
is used to inject the cells into the FH. Clearly, these re-
sults indicate that there is no need to use a cell carrier
like hydrogel or a plug after cell injection to obtain good
cell localization without dissemination throughout the
body. This is an important point as it was not possible
to inject the cells into the FH when cells were mixed
with hydrogel (data not shown). Finally, the feasibility of
this approach is supported by the commonly used treat-
ment of injection of concentrate BM in FH for the early
stages of ONFH. Effectively, no side effects and even a
positive effect have been observed in patients [3,4,43].
Our preliminary data for the efficacy of grafted autolo-
gous BMSCs in nONFH in the pig seem promising and
show a potential of BMSCs in the repair of necrosis
in vivo. However, nONFH is rare in pigs. To have a sta-
tistically relevant result of the effectiveness of BMSCs on
this painful disease, it is necessary to test this approach
on one of the models of ONFH which has been devel-
oped in either emu or pig and to conduct a study on a
large number of animals [26,44]. As the effectiveness of
BMSCs has been proven and we and others showed the
safety of this approach, the second strategy could be to
go directly to the clinic [6,7,13,14,18,40,41].
BMSC graft is a promising therapeutic approach for
treating ONFH but the other question is the effective-
ness of the BMSCs from patients with ONFH. Previousdata from Yoo et al. described the good osteogenic abil-
ities in vitro of BMSCs from patients with osteonecrosis
[45]. Altogether, these data indicate that the use of au-
tologous BMSCs for a therapeutic treatment of ONFH is
a feasible strategy.
Conclusions
In summary, we have demonstrated in a large animal
model that the intra-osseous portal is a safe and promis-
ing strategy for cell therapy treatment of FH osteonecro-
sis. As it has been previously shown that there is no risk
of transformation of hBMSCs after their amplification
and graft in vivo [18], this new study contributes to the
preclinical data which are required for the clinical appli-
cation of hBMSCs in the context of ATMPs.
Abbreviations
αMEM: alpha-modified Eagle’s medium; Alu-ISH: in situ hybridization of
human Alu sequences; ATMP: advanced therapy medicinal product;
BM: bone marrow; BMSC: bone marrow mesenchymal stromal cell; Ct: cycle
threshold; Dex: dexamethasone; DiOC18: 3, 3′-dioctadecyloxacarbocyanine
perchlorate; FCS: foetal calf serum; FH: femoral head; FS: fat saturation;
gDNA: genomic deoxyribonucleic acid; hBMSC: human bone marrow
mesenchymal stromal cell; ISH: in situ hybridization; IV: intravenous;
MRI: magnetic resonance imaging; MSC: mesenchymal stromal cell;
nONFH: natural osteonecrosis of femoral head; ONFH: osteonecrosis of the
femoral head; pBMSC: pig bone marrow mesenchymal stromal cell;
qPCR: quantitative real-time polymerase chain reaction; RT: room temperature;
SCID: severe combined immunodeficiency; SSC: sodium saline citrate.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AL carried out the BMSC culture and characterization, the biodistribution
studies in flow cytometry, molecular biology, the ectopic implantation
procedure, and all histological studies; performed data analysis and
interpretation; and drafted the manuscript. AP carried out the surgical
procedure in pigs and BM collection, participated in MRI analysis, drafted the
surgical procedure part of the Methods section, and helped to revise the
manuscript. MC performed the MRI studies and analyses and drafted the MRI
part of the Methods and Results sections. JA carried out the study of ISH of
human Alu sequences and drafted the part of Methods section
corresponding to this procedure. JL participated in the biology molecular
and flow cytometry studies and helped to revise the manuscript. PH
conceived the injection procedure in FH and participated in the surgical
procedure in pigs and in human BM collection. AR performed the MRI
studies and analyses and helped to revise the manuscript. PB participated in
the design of the study and helped to revise the manuscript. PL participated
in the conception of the study and drafted the result section corresponding
to the study of ISH of human Alu sequences. HR participated in conception
and coordination of the study and in human BM collection and helped to
revise the manuscript. NC designed and supervised the study, performed
data analysis and interpretation, and drafted the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
This work was supported by the 7th Framework Program of the European
Commission through the REBORNE (Regenerating BOne defects using New
biomedical Engineering approaches) project (Health-2009-1.4.2-241879) and
EFS Ile de France. We thank the Centre de Recherches Chirurgicales
Dominique Chopin directed by René Yiou for the use of their animal
platform facilities. The authors are grateful to Philippe Druelle and Philippe
Mario for their invaluable help during surgery and animal care. We thank the
histopathology of human and animal models service of the Pasteur Institute of
Paris and give special thanks to Laurence Fiette.
Lebouvier et al. Stem Cell Research & Therapy  (2015) 6:68 Page 13 of 14Author details
1Université Paris-Est, Faculté de médecine, Laboratoire de “Bioingénierie cellulaire,
tissulaire et sanguine”, EA3952, 5 rue Gustave Eiffel, 94000 Créteil, France.
2Etablissement Français du Sang d’Ile-de-France, Unité d’Ingénierie et de Thérapie
Cellulaire, 5 rue Gustave Eiffel, 94017 Créteil cedex, France. 3Inserm UMR955, IMRB,
51 Avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France. 4Service de
chirurgie orthopédique et traumatologie, AP-HP Hôpital Henri-Mondor, 51 Avenue
du Maréchal de Lattre de Tassigny, 94000 Créteil, France. 5Service de radiologie
Albert Chenevier, AP-HP Hôpital Henri-Mondor, 51 Avenue du Maréchal de Lattre
de Tassigny, 94000 Créteil, France. 6Inserm U957, Laboratory for Pathophysiology
of Bone Resorption, Faculty of Medicine, University of Nantes, 1 rue Gaston Veil,
44035 Nantes cedex 1, France. 7AP-HP Hôpital Henri-Mondor – A. Chenevier, Ser-
vice hospitalier, 51 Avenue du Maréchal de Lattre de Tassigny, 94000 Créteil,
France.
Received: 20 August 2014 Revised: 21 August 2014
Accepted: 4 March 2015References
1. Levasseur R. Mechanisms of osteonecrosis. Joint Bone Spine. 2008;75:639–42.
2. Hungerford DS, Jones LC. Asymptomatic osteonecrosis: Should it be
treated? Clin Orthop Relat Res. 2004;429:124–30.
3. Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone
marrow grafting. Clin Orthop Relat Res. 2002;405:14–23.
4. Gangji V, De Maertelaer V, Hauzeur JP. Autologous bone marrow cell
implantation in the treatment of non-traumatic osteonecrosis of the femoral
head: five year follow-up of a prospective controlled study. Bone.
2011;49:1005–9.
5. Wang X, Wang Y, Gou W, Lu Q, Peng J, Lu S. Role of mesenchymal stem
cells in bone regeneration and fracture repair: A review. Int Orthop.
2013;37:2491–8.
6. Petite H, Viateau V, Bensaid W, Meunier A, de Pollak C, Bourguignon M,
et al. Tissue-engineered bone regeneration. Nat Biotechnol. 2000;18:959–63.
7. Chevallier N, Anagnostou F, Zilber S, Bodivit G, Maurin S, Barrault A, et al.
Osteoblastic differentiation of human mesenchymal stem cells with platelet
lysate. Biomaterials. 2010;31:270–8.
8. Leotot J, Coquelin L, Bodivit G, Bierling P, Hernigou P, Rouard H, et al.
Platelet lysate coating on scaffolds directly and indirectly enhances cell
migration, improving bone and blood vessel formation. Acta Biomater.
2013;9:6630–40.
9. Quarto R, Mastrogiacomo M, Cancedda R, Kutepov SM, Mukhachev V,
Lavroukov A, et al. Repair of large bone defects with the use of autologous
bone marrow stromal cells. N Engl J Med. 2001;344:385–6.
10. Marcacci M, Kon E, Moukhachev V, Lavroukov A, Kutepov S, Quarto R, et al.
Stem cells associated with macroporous bioceramics for long bone repair:
6- to 7-year outcome of a pilot clinical study. Tissue Eng. 2007;13:947–55.
11. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo
distribution of bone marrow-derived mesenchymal stem cells after infusion.
Cells Tissues Organs. 2001;169:12–20.
12. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et al. Intravenous
hmscs improve myocardial infarction in mice because cells embolized in
lung are activated to secrete the anti-inflammatory protein tsg-6. Cell Stem
Cell. 2009;5:54–63.
13. Ramot Y, Meiron M, Toren A, Steiner M, Nyska A. Safety and biodistribution
profile of placental-derived mesenchymal stromal cells (plx-pad) following
intramuscular delivery. Toxicol Pathol. 2009;37:606–16.
14. Tolar J, O’Shaughnessy MJ, Panoskaltsis-Mortari A, McElmurry RT, Bell S,
Riddle M, et al. Host factors that impact the biodistribution and persistence
of multipotent adult progenitor cells. Blood. 2006;107:4182–8.
15. Toupet K, Maumus M, Peyrafitte JA, Bourin P, van Lent PL, Ferreira R,
et al. Long-term detection of human adipose-derived mesenchymal
stem cells after intraarticular injection in scid mice. Arthritis Rheum.
2013;65:1786–94.
16. Sensebe L, Fleury-Cappellesso S. Biodistribution of mesenchymal stem/stromal
cells in a preclinical setting. Stem Cells Int. 2013;2013:678063.
17. Sharpe ME, Morton D, Rossi A. Nonclinical safety strategies for stem cell
therapies. Toxicol Appl Pharmacol. 2012;262:223–31.
18. Tarte K, Gaillard J, Lataillade JJ, Fouillard L, Becker M, Mossafa H, et al.
Clinical-grade production of human mesenchymal stromal cells: Occurrence
of aneuploidy without transformation. Blood. 2010;115:1549–53.19. Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM, et al. Potential
risks of bone marrow cell transplantation into infarcted hearts. Blood.
2007;110:1362–9.
20. Zhu W, Xu W, Jiang R, Qian H, Chen M, Hu J, et al. Mesenchymal stem cells
derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol.
2006;80:267–74.
21. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, et al.
Immunosuppressive effect of mesenchymal stem cells favors tumor growth
in allogeneic animals. Blood. 2003;102:3837–44.
22. Helke KL, Swindle MM. Animal models of toxicology testing: the role of
pigs. Expert Opin Drug Metab Toxicol. 2013;9:127–39.
23. Merrifield CA, Lewis M, Claus SP, Beckonert OP, Dumas ME, Duncker S, et al.
A metabolic system-wide characterisation of the pig: A model for human
physiology. Mol Biosyst. 2011;7:2577–88.
24. Coquelin L, Fialaire-Legendre A, Roux S, Poignard A, Bierling P, Hernigou P,
et al. In vivo and in vitro comparison of three different allografts vitalized
with human mesenchymal stromal cells. Tissue Eng Part A. 2012;18:1921–31.
25. Bouderlique T, Henault E, Lebouvier A, Frescaline G, Bierling P, Rouard H,
et al. Pleiotrophin commits human bone marrow mesenchymal stromal cells
towards hypertrophy during chondrogenesis. PLoS One. 2014;9, e88287.
26. Poignard A, Lebouvier A, Cavet M, Rahmouni A, Flouzat Lachaniette CH,
Bierling P, et al. New preclinical porcine model of femoral head
osteonecrosis to test mesenchymal stromal cell efficiency in regenerative
medicine. Int Orthop. 2014;38:1837–44.
27. Ozdemir O. Evaluation of human mast cell-mediated cytotoxicity by dioc18
target cell labeling in flow cytometry. J Immunol Methods. 2007;319:98–103.
28. Redwine JM, Armstrong RC. In vivo proliferation of oligodendrocyte
progenitors expressing pdgfalphar during early remyelination. J Neurobiol.
1998;37:413–28.
29. Hernigou P, Homma Y, Flouzat Lachaniette CH, Poignard A, Allain J,
Chevallier N, et al. Benefits of small volume and small syringe for bone
marrow aspirations of mesenchymal stem cells. Int Orthop. 2013;37:2279–87.
30. Bindslev L, Haack-Sorensen M, Bisgaard K, Kragh L, Mortensen S, Hesse B,
et al. Labelling of human mesenchymal stem cells with indium-111 for
spect imaging: Effect on cell proliferation and differentiation. Eur J Nucl
Med Mol Imaging. 2006;33:1171–7.
31. Nohroudi K, Arnhold S, Berhorn T, Addicks K, Hoehn M, Himmelreich U. In
vivo MRI stem cell tracking requires balancing of detection limit and cell
viability. Cell Transplant. 2010;19:431–41.
32. Schmidtke-Schrezenmeier G, Urban M, Musyanovych A, Mailander V,
Rojewski M, Fekete N, et al. Labeling of mesenchymal stromal cells with iron
oxide-poly(l-lactide) nanoparticles for magnetic resonance imaging: Uptake,
persistence, effects on cellular function and magnetic resonance imaging
properties. Cytotherapy. 2011;13:962–75.
33. Love Z, Wang F, Dennis J, Awadallah A, Salem N, Lin Y, et al. Imaging of
mesenchymal stem cell transplant by bioluminescence and pet. J Nucl Med.
2007;48:2011–20.
34. Wang F, Dennis JE, Awadallah A, Solchaga LA, Molter J, Kuang Y, et al.
Transcriptional profiling of human mesenchymal stem cells transduced with
reporter genes for imaging. Physiol Genomics. 2009;37:23–34.
35. Warncke B, Valtink M, Weichel J, Engelmann K, Schafer H. Experimental rat
model for therapeutic retinal pigment epithelium transplantation–unequivocal
microscopic identification of human donor cells by in situ hybridisation of
human-specific alu sequences. Virchows Arch. 2004;444:74–81.
36. Niemeyer P, Szalay K, Luginbuhl R, Sudkamp NP, Kasten P. Transplantation
of human mesenchymal stem cells in a non-autogenous setting for bone
regeneration in a rabbit critical-size defect model. Acta Biomater.
2010;6:900–8.
37. Maumus M, Guerit D, Toupet K, Jorgensen C, Noel D. Mesenchymal stem
cell-based therapies in regenerative medicine: Applications in rheumatology.
Stem Cell Res Ther. 2011;2:14.
38. Piriou L, Chilmonczyk S, Genetet N, Albina E. Design of a flow cytometric
assay for the determination of natural killer and cytotoxic t-lymphocyte
activity in human and in different animal species. Cytometry.
2000;41:289–97.
39. Peterbauer-Scherb A, van Griensven M, Meinl A, Gabriel C, Redl H, Wolbank S.
Isolation of pig bone marrow mesenchymal stem cells suitable for one-step
procedures in chondrogenic regeneration. J Tissue Eng Regen Med.
2010;4:485–90.
40. Detante O, Moisan A, Dimastromatteo J, Richard MJ, Riou L, Grillon E, et al.
Intravenous administration of 99mtc-hmpao-labeled human mesenchymal
Lebouvier et al. Stem Cell Research & Therapy  (2015) 6:68 Page 14 of 14stem cells after stroke: In vivo imaging and biodistribution. Cell Transplant.
2009;18:1369–79.
41. Allers C, Sierralta WD, Neubauer S, Rivera F, Minguell JJ, Conget PA.
Dynamic of distribution of human bone marrow-derived mesenchymal stem
cells after transplantation into adult unconditioned mice. Transplantation.
2004;78:503–8.
42. Leotot J, Lebouvier A, Hernigou P, Bierling P, Rouard H, Chevallier N.
Bone-forming capacity and biodistribution of bone marrow-derived
stromal cells directly loaded into scaffolds: A novel and easy approach
for clinical application of bone regeneration. Cell Transplant.
2014 Oct 28. [Epub ahead of print].
43. Gangji V, Hauzeur JP, Matos C, De Maertelaer V, Toungouz M, Lambermont
M. Treatment of osteonecrosis of the femoral head with implantation of
autologous bone-marrow cells. A pilot study. J Bone Joint Surg Am.
2004;86-A:1153–60.
44. Conzemius MG, Brown TD, Zhang Y, Robinson RA. A new animal model of
femoral head osteonecrosis: One that progresses to human-like mechanical
failure. J Orthop Res. 2002;20:303–9.
45. Yoo JJ, Song WS, Koo KH, Yoon KS, Kim HJ. Osteogenic abilities of bone
marrow stromal cells are not defective in patients with osteonecrosis. Int
Orthop. 2009;33:867–72.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
